Small-cap Healthcare company Adicet Bio has logged a -37.9% change today on a trading volume of 5,080,923. The average volume for the stock is 616,768.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Based in Boston, United States the company has 86 full time employees and a market cap of $459,794,432.
The company is now trading -61.8% away from its average analyst target price of $28.09 per share. The 11 analysts following the stock have set target prices ranging from $21 to $34, and on average give Adicet Bio a rating of strong buy.
Over the last year, ACET shares have gone up 15.2%, which represents a difference of 30.9% when compared to the S&P 500. The stock's 52 week high is $21.87 per share whereas its 52 week low is $9.38. With its operating margins declining an average -595.2% over the last four years, Adicet Bio may not have a strong enough business to keep this trend.